Loading stock data…
$2.47-0.05 (-1.98%)
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
Genelux Corporation in the Healthcare sector is trading at $2.47 with a market capitalization of $112M. Wall Street consensus targets $18.83 (6 analysts), implying a +662.5% move over the next 12 months. The stock is currently near its 52-week low of $2.29, remaining 10.8% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0↓ | $8,000 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$9.64M↓ | -$9.17M↑ | -$9.41M↓ | -$8.19M↓ | -$7.79M |
| Net Income | -$9.47M↓ | -$8.93M↑ | -$9.25M↓ | -$7.95M↓ | -$7.46M |
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimul...